QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy

[1]  W A Ray,et al.  Antipsychotics and the risk of sudden cardiac death. , 2001, Archives of general psychiatry.

[2]  A H Glassman,et al.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. , 2001, The American journal of psychiatry.

[3]  C Antzelevitch,et al.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.

[4]  A. Camm,et al.  The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. , 2000, Cardiovascular research.

[5]  S. Ayis,et al.  QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients , 2000, The Lancet.

[6]  B. Phibbs,et al.  Torsade de pointes and low-dose oral haloperidol. , 1997, Archives of internal medicine.

[7]  T. Stern,et al.  The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. , 1995, Psychosomatics.

[8]  C. Alm,et al.  Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. , 1992, Therapeutic drug monitoring.

[9]  J. Vandenbroucke,et al.  QT Interval Prolongation Predicts Cardiovascular Mortality in an Apparently Healthy Population , 1991, Circulation.

[10]  A. Llerena,et al.  Debrisoquin oxidation polymorphism in a Spanish population , 1988, Clinical pharmacology and therapeutics.

[11]  S. Dahl,et al.  Clinical Pharmacology in Psychiatry , 1981, Palgrave Macmillan UK.